Nuvation Bio Inc. Files 8-K

Ticker: NUVB · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1811063

Sentiment: neutral

Topics: corporate-filing, financial-statements, regulation-fd

Related Tickers: NUVB

TL;DR

Nuvation Bio filed an 8-K on 6/11/25. Standard corporate update.

AI Summary

Nuvation Bio Inc. filed an 8-K on June 11, 2025, reporting on other events and financial statements. The company, formerly Panacea Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in New York, NY.

Why It Matters

This filing provides an update on Nuvation Bio's corporate activities and financial status, which is important for investors to monitor the company's ongoing operations and compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for corporate reporting and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Nuvation Bio Inc.?

The 8-K filing on June 11, 2025, serves as a current report for Nuvation Bio Inc., covering 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.

When was Nuvation Bio Inc. formerly known as?

Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp., with a date of name change on April 30, 2020.

Where are Nuvation Bio Inc.'s principal executive offices located?

Nuvation Bio Inc.'s principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036.

What is Nuvation Bio Inc.'s Standard Industrial Classification (SIC) code?

Nuvation Bio Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

What is the fiscal year end for Nuvation Bio Inc.?

The fiscal year end for Nuvation Bio Inc. is December 31 (1231).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Nuvation Bio Inc. (NUVB).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing